Title
Identification of immunodominant Bartonella bacilliformis proteins: a combined in-silico and serology approach
Date Issued
01 December 2021
Access level
open access
Resource Type
journal article
Author(s)
Dichter A.A.
Schultze T.G.
Wenigmann A.
Ballhorn W.
Latz A.
Schlüfter E.
Guerra Allison H.
Ugarte-Gil C.
Kempf V.A.J.
Publisher(s)
Elsevier Ltd
Abstract
Background: Bartonella bacilliformis is the aetiological agent of Carrión's disease, a biphasic and highly lethal illness formerly restricted to the South American Andes that is now spreading to adjacent areas. Reliable serodiagnostic approaches and vaccines are urgently needed. In this study, we aimed to identify immunodominant proteins of B bacilliformis and to establish novel and reliable serodiagnostic tools. Methods: We used a reverse vaccinology approach in combination with an analysis of heterologous genomic expression libraries to identify immunodominant proteins, on the basis of the genome sequences of B bacilliformis strains KC583 and KC584. Antigens were screened with serum samples collected from Peruvian patients with B bacilliformis infections and from German healthy blood donors without history of travel to South America. We further analysed immunoreactive proteins of B bacilliformis with immunoblotting and line blots. We used selected target proteins to develop a diagnostic ELISA. To assess the performance of this ELISA, we did receiver operating characteristic analyses to assess the area under the curve, cutoff values, sensitivities, and specificities with 95% CIs. Findings: We used serum samples obtained between Dec 23, 1990, and May 5, 2018, from 26 Peruvian patients with B bacilliformis infections and serum samples taken between Aug 28 and Aug 31, 2020, from 96 healthy German blood donors. 21 potentially immunodominant proteins were identified and recombinantly expressed, and their reactivity was assessed with immunoblotting and line blots. Of these 21 antigens, 14 were found to be immunoreactive. By using serum samples of Peruvian patients with Carrión's disease and of healthy German blood donors, we identified three antigens (porin B, autotransporter E, and hypothetical protein B) as suitable immunodominant antigens, and we applied them in a diagnostic ELISA using two different antigen combinations (porin B plus autotransporter E and porin B plus autotransporter E plus hypothetical protein B). For the combination of porin B and autotransporter E, with optical density measured at 450 nm (OD450) cutoff value of 0·29, sensitivity was 80·8% (95% CI 60·7–93·5) and specificity was 94·8% (88·3–98·3) for all Peruvian patient samples. For a combination of porin B, autotransporter E, and hypothetical protein B, with an OD450 cutoff of 0·34, sensitivity was 76·9% (56·4–91·0) and specificity was 93·8% (86·9–97·7) for all Peruvian patient samples. Interpretation: This novel ELISA could represent a useful serodiagnostic tool for future epidemiological studies of B bacilliformis in endemic areas. Additionally, the immunodominant antigens we have identified could provide a first basis for future vaccine development to prevent the highly lethal Carrión's disease. Funding: DRUID (Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases) Initiative and Robert Koch Institute. Translations: For the Spanish and Quechua translations of the abstract see Supplementary Materials section.
Start page
e685
End page
e694
Volume
2
Issue
12
Language
English
OCDE Knowledge area
Enfermedades infecciosas Medicina tropical
Scopus EID
2-s2.0-85120180896
Source
The Lancet Microbe
Resource of which it is part
The Lancet Microbe
Sponsor(s)
This work was supported by the LOEWE Center DRUID (project C2) and the Robert Koch-Institute, Berlin, Germany (Bartonella Consiliary Laboratory, 1369-354). The sequencing service was provided by the Norwegian Sequencing Centre, a national technology platform hosted by the University of Oslo (Oslo, Norway) and supported by the Functional Genomics and Infrastructure programmes of the Research Council of Norway. We thank Michael Schmidt and Erhard Seifried (German Red Cross blood service Baden-Württemberg-Hesse, Frankfurt, Germany) for providing blood donor serum samples and Eugenia Álvarez for the Quechua translation of the Summary. VAJK reports grants from the State of Hesse (LOEWE center DRUID [Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases]) and from the Robert Koch-Institute (Berlin, Germany); and has received grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, and the EU, outside of the submitted work. VAJK, AAD, and AW are inventors on a pending patent (a method for inducing an immune response against B bacilliformis in a patient; application EP21158777.9). All other authors declare no competing interests.
Sources of information: Directorio de Producción Científica Scopus